Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis

J Neuroimmunol. 2013 Oct 15;263(1-2):152-4. doi: 10.1016/j.jneuroim.2013.07.013. Epub 2013 Jul 26.

Abstract

Evidence exists that apoptotic elimination of autoreactive T lymphocytes is defective in multiple sclerosis (MS). Here, we measured serum levels of soluble forms of Fas (sFas), Fas ligand (sFasL) and TNF-related apoptosis-inducing ligand (sTRAIL) in 38 healthy controls (HC) and 92 untreated MS patients with different clinical forms and activity phases of the disease by immunoassay. Serum levels of sFas, sFasL and sTRAIL did not differ between MS patients and HC. sTRAIL levels were significantly decreased in RRMS during relapses. These findings support a role of TRAIL in the pathogenesis of MS, especially during the acute phases of the disease.

Keywords: Apoptosis; Fas; FasL; Multiple sclerosis; Relapse; TRAIL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apoptosis / immunology*
  • Apoptosis Regulatory Proteins / blood*
  • Apoptosis Regulatory Proteins / physiology
  • Biomarkers / blood
  • Down-Regulation / immunology
  • Fas Ligand Protein / blood
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / metabolism
  • Multiple Sclerosis / pathology*
  • Solubility
  • TNF-Related Apoptosis-Inducing Ligand / blood
  • Young Adult
  • fas Receptor / blood

Substances

  • Apoptosis Regulatory Proteins
  • Biomarkers
  • FAS protein, human
  • Fas Ligand Protein
  • TNF-Related Apoptosis-Inducing Ligand
  • TNFSF10 protein, human
  • fas Receptor